secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001140361-25-023362
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio stockholders approve officer exculpation amendment and 5M-share increase in stock plan
--------------------------------------------------------------------------------

- Stockholders elected all five Class III director nominees: Kumar, Homcy, Dachille, Daniels, Lo.
- Approved amendment to increase shares reserved under 2021 Stock Plan by 5,000,000 shares (128.9M for, 26.7M against).
- Approved officer exculpation amendment to limit liability of certain officers as permitted under Delaware law (151.2M for, 5.6M against).
- Ratified Deloitte & Touche as independent auditor for FY2025 (173.8M for, 56k against).
- Non-binding advisory vote on executive compensation passed (117.6M for, 37.9M against, 1.2M abstain).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125023362/0001140361-25-023362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125023362/ny20050862x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer